



**Fig. 1. Cut-off variability of DOC, APRI and FIB-4 in patient cohorts stratified by CLD etiology.**

*Abbreviations:* SD, standard deviation; CoV, coefficient of variation; DOC, dithiothreitol-oxidizing capacity; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index.




**Fig. 2. F0-1 and F2-4 variability of APRI, FIB-4 and DOC in patient cohorts stratified by CLD etiology.**

*Abbreviations:* SD, standard deviation; CoV, coefficient of variation; DOC, dithiothreitol-oxidizing capacity; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index.




**Fig. 3. Cut-off variability of DOC, APRI and FIB-4 in pooled CLD cohorts stratified by age.**

*Abbreviations:* SD, standard deviation; CoV, coefficient of variation; DOC, dithiothreitol-oxidizing capacity; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index.



**Fig. 4. F0-1 and F2-4 variability of APRI, FIB-4 and DOC in pooled CLD cohorts stratified by age.**

*Abbreviations:* SD, standard deviation; CoV, coefficient of variation; DOC, dithiothreitol-oxidizing capacity; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index.



Low cut-off	High cut-off	AUROC (95% CI)	Sens (%)	Spec (%)	NPV (%)	Excluded (%)	PPV (%)	Confirmed (≥F2) (%)
2.13	\	0.808	78.9	70.1	<b>86.0</b>	<b>52.9</b>	58.8	\
\	2.93	(0.770-0.846)	31.4	97.5	72.4	\	<b>87.1</b>	<b>12.7</b>

**Fig. 5. Diagnostic performance of DOC for significant fibrosis.** All patients with CLD were combined together for the analysis. Healthy control persons as the HC group were used for assessing the upper limit of normal.

Abbreviations: HC, healthy control; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; DOC, dithiothreitol-oxidizing capacity.